



Rep. Avery Bourne

Filed: 3/13/2017

10000HB2534ham001

LRB100 08419 RLC 23080 a

1 AMENDMENT TO HOUSE BILL 2534

2 AMENDMENT NO. _____. Amend House Bill 2534 by replacing
3 everything after the enacting clause with the following:

4 "Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 204, 206, 208, 401, and 402 as
6 follows:

7 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

8 Sec. 204. (a) The controlled substances listed in this
9 Section are included in Schedule I.

10 (b) Unless specifically excepted or unless listed in
11 another schedule, any of the following opiates, including their
12 isomers, esters, ethers, salts, and salts of isomers, esters,
13 and ethers, whenever the existence of such isomers, esters,
14 ethers and salts is possible within the specific chemical
15 designation:

16 (1) Acetylmethadol;

- 1 (1.1) Acetyl-alpha-methylfentanyl
2 (N-[1-(1-methyl-2-phenethyl)-
3 4-piperidinyl]-N-phenylacetamide);
4 (2) Allylprodine;
5 (3) Alphacetylmethadol, except
6 levo-alphacetylmethadol (also known as levo-alpha-
7 acetylmethadol, levomethadyl acetate, or LAAM);
8 (4) Alphameprodine;
9 (5) Alphamethadol;
10 (6) Alpha-methylfentanyl
11 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
12 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
13 propanilido) piperidine;
14 (6.1) Alpha-methylthiofentanyl
15 (N-[1-methyl-2-(2-thienyl)ethyl-
16 4-piperidinyl]-N-phenylpropanamide);
17 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
18 (7.1) PEPAP
19 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
20 (8) Benzethidine;
21 (9) Betacetylmethadol;
22 (9.1) Beta-hydroxyfentanyl
23 (N-[1-(2-hydroxy-2-phenethyl)-
24 4-piperidinyl]-N-phenylpropanamide);
25 (10) Betameprodine;
26 (11) Betamethadol;

- 1 (12) Betaprodine;
- 2 (13) Clonitazene;
- 3 (14) Dextromoramide;
- 4 (15) Diampromide;
- 5 (16) Diethylthiambutene;
- 6 (17) Difenoquin;
- 7 (18) Dimenoxadol;
- 8 (19) Dimepseptanol;
- 9 (20) Dimethylthiambutene;
- 10 (21) Dioxaphetylbutyrate;
- 11 (22) Dipipanone;
- 12 (23) Ethylmethylthiambutene;
- 13 (24) Etonitazene;
- 14 (25) Etoxadine;
- 15 (26) Furethidine;
- 16 (27) Hydroxypethidine;
- 17 (28) Ketobemidone;
- 18 (29) Levomoramide;
- 19 (30) Levophenacymorphan;
- 20 (31) 3-Methylfentanyl
- 21 (N-[3-methyl-1-(2-phenylethyl)-
- 22 4-piperidyl]-N-phenylpropanamide);
- 23 (31.1) 3-Methylthiofentanyl
- 24 (N-[(3-methyl-1-(2-thienyl)ethyl-
- 25 4-piperidinyl]-N-phenylpropanamide);
- 26 (32) Morpheridine;

- 1 (33) Noracymethadol;
- 2 (34) Norlevorphanol;
- 3 (35) Normethadone;
- 4 (36) Norpipanone;
- 5 (36.1) Para-fluorofentanyl
- 6 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
- 7 4-piperidinyl]propanamide);
- 8 (37) Phenadoxone;
- 9 (38) Phenampromide;
- 10 (39) Phenomorphan;
- 11 (40) Phenoperidine;
- 12 (41) Piritramide;
- 13 (42) Proheptazine;
- 14 (43) Properidine;
- 15 (44) Propiram;
- 16 (45) Racemoramide;
- 17 (45.1) Thiofentanyl
- 18 (N-phenyl-N-[1-(2-thienyl)ethyl-
- 19 4-piperidinyl]-propanamide);
- 20 (46) Tilidine;
- 21 (47) Trimeperidine;
- 22 (48) Beta-hydroxy-3-methylfentanyl (other name:
- 23 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
- 24 N-phenylpropanamide);
- 25 (49) Furanyl fentanyl (FU-F);
- 26 (50) Butyryl fentanyl;

- 1 (51) Valeryl fentanyl;
2 (52) Acetyl fentanyl;
3 (53) Beta-hydroxy-thiofentanyl;
4 (54) 3,4-dichloro-N-[2-
5 (dimethylamino)cyclohexyl]-N-
6 methylbenzamide (U-47700);
7 (55) 4-chloro-N-[1-[2-
8 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
9 benzenesulfonamide (W-18);
10 (56) 4-chloro-N-[1-(2-phenylethyl)
11 -2-piperidinylidene]-benzenesulfonamide (W-15);
12 (57) acrylfentanyl (acryloylfentanyl).

13 (c) Unless specifically excepted or unless listed in
14 another schedule, any of the following opium derivatives, its
15 salts, isomers and salts of isomers, whenever the existence of
16 such salts, isomers and salts of isomers is possible within the
17 specific chemical designation:

- 18 (1) Acetorphine;
19 (2) Acetyldihydrocodeine;
20 (3) Benzylmorphine;
21 (4) Codeine methylbromide;
22 (5) Codeine-N-Oxide;
23 (6) Cyprenorphine;
24 (7) Desomorphine;
25 (8) Diacetyldihydromorphine (Dihydroheroin);
26 (9) Dihydromorphine;

- 1 (10) Drotebanol;
- 2 (11) Etorphine (except hydrochloride salt);
- 3 (12) Heroin;
- 4 (13) Hydromorphenol;
- 5 (14) Methyldesorphine;
- 6 (15) Methyldihydromorphine;
- 7 (16) Morphine methylbromide;
- 8 (17) Morphine methylsulfonate;
- 9 (18) Morphine-N-Oxide;
- 10 (19) Myrophine;
- 11 (20) Nicocodeine;
- 12 (21) Nicomorphine;
- 13 (22) Normorphine;
- 14 (23) Pholcodine;
- 15 (24) Thebacon.

16 (d) Unless specifically excepted or unless listed in
17 another schedule, any material, compound, mixture, or
18 preparation which contains any quantity of the following
19 hallucinogenic substances, or which contains any of its salts,
20 isomers and salts of isomers, whenever the existence of such
21 salts, isomers, and salts of isomers is possible within the
22 specific chemical designation (for the purposes of this
23 paragraph only, the term "isomer" includes the optical,
24 position and geometric isomers):

- 25 (1) 3,4-methylenedioxyamphetamine
26 (alpha-methyl, 3,4-methylenedioxyphenethylamine,

1 methylenedioxyamphetamine, MDA);

2 (1.1) Alpha-ethyltryptamine

3 (some trade or other names: etryptamine;

4 MONASE; alpha-ethyl-1H-indole-3-ethanamine;

5 3-(2-aminobutyl)indole; a-ET; and AET);

6 (2) 3,4-methylenedioxymethamphetamine (MDMA);

7 (2.1) 3,4-methylenedioxy-N-ethylamphetamine

8 (also known as: N-ethyl-alpha-methyl-

9 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,

10 and MDEA);

11 (2.2) N-Benzylpiperazine (BZP);

12 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);

13 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);

14 (4) 3,4,5-trimethoxyamphetamine (TMA);

15 (5) (Blank);

16 (6) Diethyltryptamine (DET);

17 (7) Dimethyltryptamine (DMT);

18 (7.1) 5-Methoxy-diallyltryptamine;

19 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);

20 (9) Ibogaine (some trade and other names:

21 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-

22 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]

23 indole; Tabernanthe iboga);

24 (10) Lysergic acid diethylamide;

25 (10.1) Salvinorin A;

26 (10.5) Salvia divinorum (meaning all parts of the plant

1 presently classified botanically as *Salvia divinorum*,
2 whether growing or not, the seeds thereof, any extract from
3 any part of that plant, and every compound, manufacture,
4 salts, isomers, and salts of isomers whenever the existence
5 of such salts, isomers, and salts of isomers is possible
6 within the specific chemical designation, derivative,
7 mixture, or preparation of that plant, its seeds or
8 extracts);

9 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

10 (12) Peyote (meaning all parts of the plant presently
11 classified botanically as *Lophophora williamsii* Lemaire,
12 whether growing or not, the seeds thereof, any extract from
13 any part of that plant, and every compound, manufacture,
14 salts, derivative, mixture, or preparation of that plant,
15 its seeds or extracts);

16 (13) N-ethyl-3-piperidyl benzilate (JB 318);

17 (14) N-methyl-3-piperidyl benzilate;

18 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
19 (also known as N-hydroxy-alpha-methyl-
20 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

21 (15) Parahexyl; some trade or other names:
22 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
23 dibenzo (b,d) pyran; Synhexyl;

24 (16) Psilocybin;

25 (17) Psilocyn;

26 (18) Alpha-methyltryptamine (AMT);

- 1 (19) 2,5-dimethoxyamphetamine
2 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
- 3 (20) 4-bromo-2,5-dimethoxyamphetamine
4 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
5 4-bromo-2,5-DMA);
- 6 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
7 Some trade or other names: 2-(4-bromo-
8 2,5-dimethoxyphenyl)-1-aminoethane;
9 alpha-desmethyl DOB, 2CB, Nexus;
- 10 (21) 4-methoxyamphetamine
11 (4-methoxy-alpha-methylphenethylamine;
12 paramethoxyamphetamine; PMA);
- 13 (22) (Blank);
- 14 (23) Ethylamine analog of phencyclidine.
15 Some trade or other names:
16 N-ethyl-1-phenylcyclohexylamine,
17 (1-phenylcyclohexyl) ethylamine,
18 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
- 19 (24) Pyrrolidine analog of phencyclidine. Some trade
20 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
21 PHP;
- 22 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 23 (26) 2,5-dimethoxy-4-ethylamphetamine
24 (another name: DOET);
- 25 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
26 (another name: TCPy);

1 (28) (Blank);

2 (29) Thiophene analog of phencyclidine (some trade
3 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
4 2-thienyl analog of phencyclidine; TPCP; TCP);

5 (29.1) Benzothiophene analog of phencyclidine Some
6 trade or other names: BTCP or benocyclidine;

7 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);

8 (30) Bufotenine (some trade or other names:
9 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
10 3-(2-dimethylaminoethyl)-5-indolol;
11 5-hydroxy-N,N-dimethyltryptamine;
12 N,N-dimethylserotonin; mappine);

13 (31) (Blank); ~~1-Pentyl-3-(1-naphthoyl)indole~~
14 ~~Some trade or other names: JWH 018;~~

15 (32) (Blank); ~~1-Butyl-3-(1-naphthoyl)indole~~
16 ~~Some trade or other names: JWH 073;~~

17 (33) (Blank); ~~1-[(5-fluoropentyl)-1H-indol-3-yl]-~~
18 ~~(2-iodophenyl)methanone~~
19 ~~Some trade or other names: AM 694;~~

20 (34) (Blank); ~~2-[(1R,3S)-3-hydroxycyclohexyl]-5-~~
21 ~~(2-methyloctan-2-yl)phenol~~
22 ~~Some trade or other names: CP 47,497~~
23 ~~and its C6, C8 and C9 homologs;~~

24 (34.5) (Blank); ~~2-[(1R,3S)-3-hydroxycyclohexyl]-5-~~
25 ~~(2-methyloctan-2-yl)phenol), where side chain n=5;~~
26 ~~and homologues where side chain n=4, 6, or 7; Some~~

1 ~~trade or other names: CP 47, 497;~~

2 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
3 (2-methyloctan-2-yl)-6a,7,
4 10,10a-tetrahydrobenzo[c]chromen-1-ol

5 Some trade or other names: HU-210;

6 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
7 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
8 tetrahydrobenzo[c]chromen-1-ol, its isomers,
9 salts, and salts of isomers; Some trade or other
10 names: HU-210, Dexanabinol;

11 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
12 6,6-dimethyl-3-(2-methyloctan-2-yl)-
13 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

14 Some trade or other names: HU-211;

15 (37) (Blank); ~~(2-methyl-1-propyl-1H-indol-~~
16 ~~3-yl)-1-naphthalenyl-methanone~~

17 ~~Some trade or other names: JWH 015;~~

18 (38) (Blank); ~~4-methoxynaphthalen-1-yl-~~
19 ~~(1-pentylindol-3-yl)methanone~~

20 ~~Some trade or other names: JWH 081;~~

21 (39) (Blank); ~~1-Pentyl-3-(4-methyl-1-naphthoyl)indole~~

22 ~~Some trade or other names: JWH 122;~~

23 (40) (Blank); ~~2-(2-methylphenyl)-1-(1-pentyl-~~
24 ~~1H-indol-3-yl)ethanone~~

25 ~~Some trade or other names: JWH 251;~~

26 (41) (Blank); ~~1-(2-cyclohexylethyl)-3-~~

1 ~~(2-methoxyphenylacetyl)indole~~

2 ~~Some trade or other names: RCS-8, BTW-8 and SR-18;~~

3 (42) Any compound structurally derived from
4 3-(1-naphthoyl)indole or 1H-indol-3-yl-
5 (1-naphthyl)methane by substitution at the
6 nitrogen atom of the indole ring by alkyl, haloalkyl,
7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
8 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
9 or 2-(4-morpholinyl)ethyl whether or not further
10 substituted in the indole ring to any extent, whether
11 or not substituted in the naphthyl ring to any extent.
12 Examples of this structural class include, but are
13 not limited to, JWH-018, AM-2201, JWH-175, JWH-184,
14 and JWH-185;

15 (43) Any compound structurally derived from
16 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
17 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
18 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
19 aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
20 or 2-(4-morpholinyl)ethyl, whether or not further
21 substituted in the pyrrole ring to any extent, whether
22 or not substituted in the naphthyl ring to any extent.
23 Examples of this structural class include, but are not
24 limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
25 JWH-368;

26 (44) Any compound structurally derived from

1 1-(1-naphthylmethyl)indene by substitution
2 at the 3-position of the indene ring by alkyl, haloalkyl,
3 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
4 halide, alkyl aryl halide, 1-(N-methyl-
5 2-piperidinyl)methyl, or 2-(4-
6 morpholinyl)ethyl whether or not further substituted in
7 the indene ring to any extent, whether or not substituted
8 in the naphthyl ring to any extent. Examples of
9 this structural class include, but are not
10 limited to, JWH-176;

11 (45) Any compound structurally derived from
12 3-phenylacetylindole by substitution at the
13 nitrogen atom of the indole ring with alkyl, haloalkyl,
14 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
15 halide, alkyl aryl halide, 1-(N-methyl-2-
16 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
17 whether or not further substituted in the indole ring
18 to any extent, whether or not substituted in the phenyl
19 ring to any extent. Examples of this structural
20 class include, but are not limited to, JWH-167,
21 JWH-250, JWH-251, and RCS-8;

22 (46) Any compound structurally derived from
23 2-(3-hydroxycyclohexyl)phenol by substitution
24 at the 5-position of the phenolic ring by alkyl,
25 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
26 aryl halide, alkyl aryl halide, 1-(N-methyl-2-

1 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
2 whether or not substituted in the cyclohexyl ring to any
3 extent. Examples of this structural class
4 include, but are not limited to, CP 47,
5 497 and its C8 homologue (cannabicyclohexanol);

6 (46.1) Any compound structurally
7 derived from Benzoylindoles: ~~Any compound~~
8 ~~containing a~~ 3-(benzoyl) indole ~~structure~~ with
9 substitution at the nitrogen atom of the
10 indole ring by an alkyl, haloalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl,
12 aryl halide, alkyl aryl halide,
13 1-(N-methyl-2-piperidinyl)methyl,
14 or 2-(4-morpholinyl)ethyl group
15 whether or not further substituted
16 in the indole ring to any extent and
17 whether or not substituted in the phenyl ring
18 to any extent. Examples of this structural class
19 include, but are not limited, to, AM-630,
20 AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4;

21 (47) (Blank); 3,4-Methylenedioxymethcathinone
22 ~~Some trade or other names: Methylone;~~

23 (48) (Blank); 3,4-Methylenedioxypropylone
24 ~~Some trade or other names: MDPV;~~

25 (49) (Blank); 4-Methylmethcathinone
26 ~~Some trade or other names: Mephedrone;~~

1 (50) (Blank); ~~4-methoxymethcathinone;~~

2 (51) (Blank); ~~4-Fluoromethcathinone;~~

3 (52) (Blank); ~~3-Fluoromethcathinone;~~

4 (53) 2,5-Dimethoxy-4-(n)-propylthio-
5 phenethylamine;

6 Some trade or other names: 2C-T-7;

7 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine

8 Some trade or other names: 2C-E;

9 (53.2) 2,5-dimethoxy-4-methylphenethylamine

10 Some trade or other names: 2C-D;

11 (53.3) 4-chloro-2,5-dimethoxyphenethylamine

12 Some trade or other names: 2C-C;

13 (53.4) 4-iodo-2,5-dimethoxyphenethylamine

14 Some trade or other names: 2C-I;

15 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine

16 Some trade or other names: 2C-T-2;

17 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine

18 Some trade or other names: 2C-T-4;

19 (53.7) 2,5-dimethoxyphenethylamine

20 Some trade or other names: 2C-H;

21 (53.8) 2,5-dimethoxy-4-nitrophenethylamine

22 Some trade or other names: 2C-N;

23 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine

24 Some trade or other names: 2C-P;

25 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine

26 Some trade or other names: 2C-G;

1 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
2 phenethylamine referred to in subparagraphs (20.1), (53),
3 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
4 (53.8), (53.9), and (53.10) including, but not limited to,
5 25I-NBOMe and 25C-NBOMe;

6 (54) 5-Methoxy-N,N-diisopropyltryptamine;

7 (55) (Blank); Pentedrone;

8 (56) (Blank); 4-iodo-2,5-dimethoxy-N-((2-methoxy
9 ~~phenyl)methyl)-benzeneethanamine~~
10 ~~(trade or other name: 25I-NBOMe);~~

11 (57) (Blank); 4-chloro-2,5-dimethoxy-
12 ~~N-[(2-methoxyphenyl)methyl]-benzeneethanamine~~
13 ~~(trade or other name: 25C-NBOMe);~~

14 (58) (Blank); 4-bromo-2,5-dimethoxy
15 ~~N-[(2-methoxyphenyl)methyl]-benzeneethanamine~~
16 ~~(trade or other name: 25B-NBOMe);~~

17 (59) 3-cyclopropoylindole with
18 substitution at the nitrogen atom of the
19 indole ring by alkyl, haloalkyl, alkenyl,
20 cycloalkylmethyl, cycloalkylethyl, aryl
21 halide, alkyl aryl halide,
22 1-(N-methyl-2-piperidinyl)methyl, or
23 2-(4-morpholinyl)ethyl, whether or not
24 further substituted on the indole ring
25 to any extent, whether or not substituted
26 on the cyclopropyl ring to any extent:

1 including, but not limited to, XLR11,
2 UR144, FUB-144;

3 (60) 3-adamantoylindole with
4 substitution at the nitrogen atom of the
5 indole ring by alkyl, haloalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl,
7 aryl halide, alkyl aryl halide,
8 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl, whether or not
10 further substituted on the indole ring to
11 any extent, whether or not substituted on
12 the adamantyl ring to any extent: including,
13 but not limited to, AB-001;

14 (61) N-(adamantyl)-indole-3-carboxamide
15 with substitution at the nitrogen atom of the
16 indole ring by alkyl, haloalkyl, alkenyl,
17 cycloalkylmethyl, cycloalkylethyl, aryl halide,
18 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
19 or 2-(4-morpholinyl)ethyl, whether or not further
20 substituted on the indole ring to any extent, whether
21 or not substituted on the adamantyl ring to any
22 extent: including, but not limited to,
23 APICA/2NE-1, STS-135;

24 (62) N-(adamantyl)-indazole-3-carboxamide
25 with substitution at a nitrogen atom of the indazole
26 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,

1 cycloalkylethyl, aryl halide, alkyl aryl halide,
2 1-(N-methyl-2-piperidinyl)methyl, or
3 2-(4-morpholinyl)ethyl, whether or not further
4 substituted on the indazole ring to any extent,
5 whether or not substituted on the adamantyl
6 ring to any extent: including, but not limited
7 to, AKB48, 5F-AKB48;

8 (63) 1H-indole-3-carboxylic acid 8-quinolinyl
9 ester with substitution at the nitrogen atom of the
10 indole ring by alkyl, haloalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
12 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
13 2-(4-morpholinyl)ethyl, whether or not further
14 substituted on the indole ring to any extent,
15 whether or not substituted on the quinoline ring
16 to any extent: including, but not limited to, PB22,
17 5F-PB22, FUB-PB-22;

18 (64) 3-(1-naphthoyl)indazole with
19 substitution at the nitrogen atom of the
20 indazole ring by alkyl, haloalkyl,
21 alkenyl, cycloalkylmethyl, cycloalkylethyl,
22 aryl halide, alkyl aryl halide,
23 1-(N-methyl-2-piperidinyl)methyl, or
24 2-(4-morpholinyl)ethyl, whether or not further
25 substituted on the indazole ring to any extent,
26 whether or not substituted on the naphthyl ring

1 to any extent: including, but not limited to,
2 THJ-018, THJ-2201;

3 (65) 2-(1-naphthoyl)benzimidazole with
4 substitution at the nitrogen atom of the benzimidazole
5 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
6 cycloalkylethyl, aryl halide, alkyl aryl halide,
7 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further
9 substituted on the benzimidazole ring to any extent,
10 whether or not substituted on the naphthyl ring to
11 any extent: including, but not limited to, FUBIMINA;

12 (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)
13 -1H-indazole-3-carboxamide with substitution on the
14 nitrogen atom of the indazole ring by alkyl,
15 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
16 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
17 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
18 whether or not further substituted on the indazole
19 ring to any extent: including, but not limited to,
20 AB-PINACA, AB-FUBINACA, AB-CHMINACA;

21 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-
22 2-yl)-1H-indazole-3-carboxamide with substitution
23 on the nitrogen atom of the indazole ring by alkyl,
24 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
25 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
26 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether

1 or not further substituted on the indazole ring to any
2 extent: including, but not limited to, ADB-PINACA,
3 ADB-FUBINACA;

4 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
5 1H-indole-3-carboxamide with substitution on the nitrogen
6 atom of the indole ring by alkyl, haloalkyl, alkenyl,
7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
8 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl, whether or not further
10 substituted on the indole ring to any extent:
11 including, but not limited to, ADBICA, 5F-ADBICA;

12 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-
13 1H-indole-3-carboxamide with substitution on the
14 nitrogen atom of the indole ring by alkyl, haloalkyl,
15 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
16 halide, alkyl aryl halide, 1-(N-methyl-2-
17 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
18 whether or not further substituted on the indole
19 ring to any extent: including, but not limited
20 to, ABICA, 5F-ABICA;

21 (70) Methyl 2-(1H-indazole-3-carboxamido)-
22 3-methylbutanoate with substitution on the nitrogen
23 atom of the indazole ring by alkyl, haloalkyl,
24 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
25 halide, alkyl aryl halide, 1-(N-methyl-2-
26 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,

1 whether or not further substituted on the indazole
2 ring to any extent: including, but not limited to, AMB,
3 5F-AMB.

4 (71) Methyl 2-(1H-indazole-3-carboxamido)
5 -3,3-dimethylbutanoate with substitution on the nitrogen
6 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
8 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-
9 (4-morpholinyl)ethyl, whether or not further substituted
10 on the indazole ring to any extent: including, but not
11 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

12 (72) Methyl 2-(1H-indole-3-carboxamido)-
13 3-methylbutanoate with substitution on the nitrogen atom
14 of the indole ring by alkyl, haloalkyl, alkenyl,
15 cycloalkylmethyl, cycloalkylethyl, aryl halide,
16 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
17 or 2-(4-morpholinyl)ethyl, whether or not further
18 substituted on the indazole ring to any extent:
19 including, but not limited to, MMB018, MMB2201,
20 and AMB-CHMICA;

21 (73) Methyl 2-(1H-indole-3-
22 carboxamido)-3,3-dimethylbutanoate with substitution
23 on the nitrogen atom of the indole ring by alkyl,
24 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
25 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
26 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,

1 whether or not further substituted on the
2 indazole ring to any extent: including, but
3 not limited to, MDMA-CHMICA;

4 (74) N-(1-Amino-1-oxo-3-phenylpropan
5 -2-yl) -1H-indazole-3-carboxamide with
6 substitution on the nitrogen atom of the indazole
7 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
8 cycloalkylethyl, aryl halide, alkyl aryl halide,
9 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-
10 morpholinyl)ethyl, whether or not further
11 substituted on the indazole ring to any
12 extent: including, but not limited to, APP-CHMINACA,
13 5-fluoro-APP-PINACA;

14 (75) N-(1-Amino-1-oxo-3-phenylpropan
15 -2-yl)-1H-indole-3-carboxamide with substitution on
16 the nitrogen atom of the indole ring by alkyl,
17 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
18 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
19 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
20 whether or not further substituted on the indazole
21 ring to any extent: including, but not limited to,
22 APP-PICA and 5-fluoro-APP-PICA;

23 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
24 4-AcO-DMT;

25 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: Trade
26 name 5-MeO-MIPT;

- 1 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
2 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
3 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
4 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
5 (4-HO-MiPT);
6 (82) Fluorophenylpiperazine;
7 (83) Methoxetamine;
8 (84) 1-(Ethylamino)-2-phenylpropan-2-
9 one (iso-ethcathinone).

10 (e) Unless specifically excepted or unless listed in
11 another schedule, any material, compound, mixture, or
12 preparation which contains any quantity of the following
13 substances having a depressant effect on the central nervous
14 system, including its salts, isomers, and salts of isomers
15 whenever the existence of such salts, isomers, and salts of
16 isomers is possible within the specific chemical designation:

- 17 (1) mecloqualone;
18 (2) methaqualone; and
19 (3) gamma hydroxybutyric acid.

20 (f) Unless specifically excepted or unless listed in
21 another schedule, any material, compound, mixture, or
22 preparation which contains any quantity of the following
23 substances having a stimulant effect on the central nervous
24 system, including its salts, isomers, and salts of isomers:

- 25 (1) Fenethylamine;
26 (2) N-ethylamphetamine;

1 (3) Aminorex (some other names:
2 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
3 4-5-dihydro-5-phenyl-2-oxazolamine) and its
4 salts, optical isomers, and salts of optical isomers;

5 (4) Methcathinone (some other names:
6 2-methylamino-1-phenylpropan-1-one;
7 Ephedrone; 2-(methylamino)-propiofenone;
8 alpha-(methylamino)propiofenone; N-methylcathinone;
9 methycathinone; Monomethylpropion; UR 1431) and its
10 salts, optical isomers, and salts of optical isomers;

11 (5) Cathinone (some trade or other names:
12 2-aminopropiofenone; alpha-aminopropiofenone;
13 2-amino-1-phenyl-propanone; norephedrone);

14 (6) N,N-dimethylamphetamine (also known as:
15 N,N-alpha-trimethyl-benzeneethanamine;
16 N,N-alpha-trimethylphenethylamine);

17 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
18 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);

19 (8) 3,4-Methylenedioxypropylamphetamine (MDPV);

20 (9) Halogenated amphetamines and
21 methamphetamines - any compound derived from either
22 amphetamine or methamphetamine through the substitution
23 of a halogen on the phenyl ring, including, but not
24 limited to, 2-fluoroamphetamine, 3-
25 fluoroamphetamine and 4-fluoroamphetamine;

26 (10) Aminopropylbenzofuran (APB):

1 including 4-(2-Aminopropyl) benzofuran, 5-
2 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
3 benzofuran, and 7-(2-Aminopropyl) benzofuran;

4 (11) Aminopropyldihydrobenzofuran (APDB):
5 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
6 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
7 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
8 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;

9 (12) Methylaminopropylbenzofuran
10 (MAPB): including 4-(2-methylaminopropyl)
11 benzofuran, 5-(2-methylaminopropyl)benzofuran,
12 6-(2-methylaminopropyl)benzofuran
13 and 7-(2-methylaminopropyl)benzofuran.

14 (g) Temporary listing of substances subject to emergency
15 scheduling. Any material, compound, mixture, or preparation
16 that contains any quantity of the following substances:

17 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
18 (benzylfentanyl), its optical isomers, isomers, salts,
19 and salts of isomers;

20 (2) N-[1(2-thienyl)
21 methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
22 its optical isomers, salts, and salts of isomers.

23 (h) Synthetic cathinones. Unless specifically excepted,
24 any chemical compound which is not approved by the United
25 States Food and Drug Administration or, if approved, is not
26 dispensed or possessed in accordance with State or federal law,

1 not including bupropion, structurally derived from
2 2-aminopropan-1-one by substitution at the 1-position with
3 either phenyl, naphthyl, or thiophene ring systems, whether or
4 not the compound is further modified in one or more of the
5 following ways:

6 (1) by substitution in the ring system to
7 any extent with alkyl, alkylendioxy, alkoxy,
8 haloalkyl, hydroxyl, or halide substituents, whether
9 or not further substituted in the ring system
10 by one or more other univalent substituents.
11 Examples of this class include, but are not
12 limited to, 3,4-Methylenedioxcathinone
13 (bk-MDA);

14 (2) by substitution at the 3-position
15 with an acyclic alkyl substituent. Examples of
16 this class include, but are not limited to,
17 2-methylamino-1-phenylbutan-1-one
18 (buphedrone); or

19 (3) by substitution at the 2-amino nitrogen
20 atom with alkyl, dialkyl, benzyl, or methoxybenzyl
21 groups, or by inclusion of the 2-amino nitrogen atom
22 in a cyclic structure. Examples of this class include,
23 but are not limited to, Dimethylcathinone, Ethcathinone,
24 and α -Pyrrolidinopropiophenone (α -PPP).

25 (Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised
26 10-25-16.)

1 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)

2 Sec. 206. (a) The controlled substances listed in this
3 Section are included in Schedule II.

4 (b) Unless specifically excepted or unless listed in
5 another schedule, any of the following substances whether
6 produced directly or indirectly by extraction from substances
7 of vegetable origin, or independently by means of chemical
8 synthesis, or by combination of extraction and chemical
9 synthesis:

10 (1) Opium and opiates, and any salt, compound,
11 derivative or preparation of opium or opiate, excluding
12 apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
13 nalmefene, naloxone, and naltrexone, and their respective
14 salts, but including the following:

- 15 (i) Raw Opium;
16 (ii) Opium extracts;
17 (iii) Opium fluid extracts;
18 (iv) Powdered opium;
19 (v) Granulated opium;
20 (vi) Tincture of opium;
21 (vii) Codeine;
22 (viii) Ethylmorphine;
23 (ix) Etorphine Hydrochloride;
24 (x) Hydrocodone;
25 (xi) Hydromorphone;

1 (xii) Metopon;

2 (xiii) Morphine;

3 (xiii.5) 6-Monoacetylmorphine;

4 (xiv) Oxycodone;

5 (xv) Oxymorphone;

6 (xv.5) Tapentadol;

7 (xvi) Thebaine;

8 (xvii) Thebaine-derived butorphanol.

9 (xviii) Methorphan ~~Dextromethorphan~~, except drug
10 products containing dextromethorphan that may be
11 dispensed pursuant to a prescription order of a
12 practitioner and are sold in compliance with the safety
13 and labeling standards as set forth by the United
14 States Food and Drug Administration, or drug products
15 containing dextromethorphan that are sold in solid,
16 tablet, liquid, capsule, powder, thin film, or gel form
17 and which are formulated, packaged, and sold in dosages
18 and concentrations for use as an over-the-counter drug
19 product. For the purposes of this Section,
20 "over-the-counter drug product" means a drug that is
21 available to consumers without a prescription and sold
22 in compliance with the safety and labeling standards as
23 set forth by the United States Food and Drug
24 Administration.

25 (2) Any salt, compound, isomer, derivative or
26 preparation thereof which is chemically equivalent or

1 identical with any of the substances referred to in
2 subparagraph (1), but not including the isoquinoline
3 alkaloids of opium;

4 (3) Opium poppy and poppy straw;

5 (4) Coca leaves and any salt, compound, isomer, salt of
6 an isomer, derivative, or preparation of coca leaves
7 including cocaine or ecgonine, and any salt, compound,
8 isomer, derivative, or preparation thereof which is
9 chemically equivalent or identical with any of these
10 substances, but not including decocainized coca leaves or
11 extractions of coca leaves which do not contain cocaine or
12 ecgonine (for the purpose of this paragraph, the term
13 "isomer" includes optical, positional and geometric
14 isomers);

15 (5) Concentrate of poppy straw (the crude extract of
16 poppy straw in either liquid, solid or powder form which
17 contains the phenanthrine alkaloids of the opium poppy).

18 (c) Unless specifically excepted or unless listed in
19 another schedule any of the following opiates, including their
20 isomers, esters, ethers, salts, and salts of isomers, whenever
21 the existence of these isomers, esters, ethers and salts is
22 possible within the specific chemical designation, dextrorphan
23 excepted:

24 (1) Alfentanil;

25 (1.1) Carfentanil;

26 (1.2) Thiafentanyl;

- 1 (2) Alphaprodine;
- 2 (3) Anileridine;
- 3 (4) Bezitramide;
- 4 (5) Bulk Dextropropoxyphene (non-dosage forms);
- 5 (6) Dihydrocodeine;
- 6 (7) Diphenoxylate;
- 7 (8) Fentanyl;
- 8 (9) Sufentanil;
- 9 (9.5) Remifentanil;
- 10 (10) Isomethadone;
- 11 (11) (Blank); ~~Levomethorphan~~;
- 12 (12) Levorphanol (Levorphan);
- 13 (13) Metazocine;
- 14 (14) Methadone;
- 15 (15) Methadone-Intermediate,
- 16 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
- 17 (16) Moramide-Intermediate,
- 18 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
- 19 acid;
- 20 (17) Pethidine (meperidine);
- 21 (18) Pethidine-Intermediate-A,
- 22 4-cyano-1-methyl-4-phenylpiperidine;
- 23 (19) Pethidine-Intermediate-B,
- 24 ethyl-4-phenylpiperidine-4-carboxylate;
- 25 (20) Pethidine-Intermediate-C,
- 26 1-methyl-4-phenylpiperidine-4-carboxylic acid;

1 (21) Phenazocine;

2 (22) Piminodine;

3 (23) Racemethorphan;

4 (24) (Blank); ~~Racemorphan~~;

5 (25) Levo-alpha-acetylmethadol (some other names:
6 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).

7 (d) Unless specifically excepted or unless listed in
8 another schedule, any material, compound, mixture, or
9 preparation which contains any quantity of the following
10 substances having a stimulant effect on the central nervous
11 system:

12 (1) Amphetamine, its salts, optical isomers, and salts
13 of its optical isomers;

14 (2) Methamphetamine, its salts, isomers, and salts of
15 its isomers;

16 (3) Phenmetrazine and its salts;

17 (4) Methylphenidate;

18 (5) Lisdexamfetamine.

19 (e) Unless specifically excepted or unless listed in
20 another schedule, any material, compound, mixture, or
21 preparation which contains any quantity of the following
22 substances having a depressant effect on the central nervous
23 system, including its salts, isomers, and salts of isomers
24 whenever the existence of such salts, isomers, and salts of
25 isomers is possible within the specific chemical designation:

26 (1) Amobarbital;

- 1 (2) Secobarbital;
- 2 (3) Pentobarbital;
- 3 (4) Pentazocine;
- 4 (5) Phencyclidine;
- 5 (6) Gluthethimide;
- 6 (7) (Blank).

7 (f) Unless specifically excepted or unless listed in
8 another schedule, any material, compound, mixture, or
9 preparation which contains any quantity of the following
10 substances:

11 (1) Immediate precursor to amphetamine and
12 methamphetamine:

13 (i) Phenylacetone

14 Some trade or other names: phenyl-2-propanone;
15 P2P; benzyl methyl ketone; methyl benzyl ketone.

16 (2) Immediate precursors to phencyclidine:

17 (i) 1-phenylcyclohexylamine;

18 (ii) 1-piperidinocyclohexanecarbonitrile (PCC).

19 (3) Nabilone.

20 (Source: P.A. 97-334, eff. 1-1-12.)

21 (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)

22 Sec. 208. (a) The controlled substances listed in this
23 Section are included in Schedule III.

24 (b) Unless specifically excepted or unless listed in
25 another schedule, any material, compound, mixture, or

1 preparation which contains any quantity of the following
2 substances having a stimulant effect on the central nervous
3 system, including its salts, isomers (whether optical
4 position, or geometric), and salts of such isomers whenever the
5 existence of such salts, isomers, and salts of isomers is
6 possible within the specific chemical designation;

7 (1) Those compounds, mixtures, or preparations in
8 dosage unit form containing any stimulant substances
9 listed in Schedule II which compounds, mixtures, or
10 preparations were listed on August 25, 1971, as excepted
11 compounds under Title 21, Code of Federal Regulations,
12 Section 308.32, and any other drug of the quantitative
13 composition shown in that list for those drugs or which is
14 the same except that it contains a lesser quantity of
15 controlled substances;

16 (2) Benzphetamine;

17 (3) Chlorphentermine;

18 (4) Clortermine;

19 (5) Phendimetrazine.

20 (c) Unless specifically excepted or unless listed in
21 another schedule, any material, compound, mixture, or
22 preparation which contains any quantity of the following
23 substances having a potential for abuse associated with a
24 depressant effect on the central nervous system:

25 (1) Any compound, mixture, or preparation containing
26 amobarbital, secobarbital, pentobarbital or any salt

1 thereof and one or more other active medicinal ingredients
2 which are not listed in any schedule;

3 (2) Any suppository dosage form containing
4 amobarbital, secobarbital, pentobarbital or any salt of
5 any of these drugs and approved by the Federal Food and
6 Drug Administration for marketing only as a suppository;

7 (3) Any substance which contains any quantity of a
8 derivative of barbituric acid, or any salt thereof:

9 (3.1) Aprobarbital;

10 (3.2) Butabarbital (secbutabarbital);

11 (3.3) Butalbital;

12 (3.4) Butobarbital (butethal);

13 (4) Chlorhexadol;

14 (5) Methyprylon;

15 (6) Sulfondiethylmethane;

16 (7) Sulfonethylmethane;

17 (8) Sulfonmethane;

18 (9) Lysergic acid;

19 (10) Lysergic acid amide;

20 (10.1) Tiletamine or zolazepam or both, or any salt of
21 either of them.

22 Some trade or other names for a tiletamine-zolazepam
23 combination product: Telazol.

24 Some trade or other names for Tiletamine:

25 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

26 Some trade or other names for zolazepam:

1 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
2 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrzapon.

3 (11) Any material, compound, mixture or preparation
4 containing not more than 12.5 milligrams of pentazocine or
5 any of its salts, per 325 milligrams of aspirin;

6 (12) Any material, compound, mixture or preparation
7 containing not more than 12.5 milligrams of pentazocine or
8 any of its salts, per 325 milligrams of acetaminophen;

9 (13) Any material, compound, mixture or preparation
10 containing not more than 50 milligrams of pentazocine or
11 any of its salts plus naloxone HCl USP 0.5 milligrams, per
12 dosage unit;

13 (14) Ketamine;

14 (15) Thiopental.

15 (d) Nalorphine.

16 (d.5) Buprenorphine.

17 (e) Unless specifically excepted or unless listed in
18 another schedule, any material, compound, mixture, or
19 preparation containing limited quantities of any of the
20 following narcotic drugs, or their salts calculated as the free
21 anhydrous base or alkaloid, as set forth below:

22 (1) not more than 1.8 grams of codeine per 100
23 milliliters or not more than 90 milligrams per dosage unit,
24 with an equal or greater quantity of an isoquinoline
25 alkaloid of opium;

26 (2) not more than 1.8 grams of codeine per 100

1 milliliters or not more than 90 milligrams per dosage unit,
2 with one or more active non-narcotic ingredients in
3 recognized therapeutic amounts;

4 (3) (blank); ~~not more than 300 milligrams of~~
5 ~~dihydrocodeinone per 100 milliliters or not more than 15~~
6 ~~milligrams per dosage unit, with a fourfold or greater~~
7 ~~quantity of an isoquinoline alkaloid of opium;~~

8 (4) (blank); ~~not more than 300 milligrams of~~
9 ~~dihydrocodeinone per 100 milliliters or not more than 15~~
10 ~~milligrams per dosage unit, with one or more active,~~
11 ~~non-narcotic ingredients in recognized therapeutic~~
12 ~~amounts;~~

13 (5) not more than 1.8 grams of dihydrocodeine per 100
14 milliliters or not more than 90 milligrams per dosage unit,
15 with one or more active, non-narcotic ingredients in
16 recognized therapeutic amounts;

17 (6) not more than 300 milligrams of ethylmorphine per
18 100 milliliters or not more than 15 milligrams per dosage
19 unit, with one or more active, non-narcotic ingredients in
20 recognized therapeutic amounts;

21 (7) not more than 500 milligrams of opium per 100
22 milliliters or per 100 grams, or not more than 25
23 milligrams per dosage unit, with one or more active,
24 non-narcotic ingredients in recognized therapeutic
25 amounts;

26 (8) not more than 50 milligrams of morphine per 100

1 milliliters or per 100 grams with one or more active,
2 non-narcotic ingredients in recognized therapeutic
3 amounts.

4 (f) Anabolic steroids, except the following anabolic
5 steroids that are exempt:

6 (1) Androgyn L.A.;

7 (2) Andro-Estro 90-4;

8 (3) depANDROGYN;

9 (4) DEPO-T.E.;

10 (5) depTESTROGEN;

11 (6) Duomone;

12 (7) DURATESTRIN;

13 (8) DUO-SPAN II;

14 (9) Estratest;

15 (10) Estratest H.S.;

16 (11) PAN ESTRA TEST;

17 (12) Premarin with Methyltestosterone;

18 (13) TEST-ESTRO Cypionates;

19 (14) Testosterone Cyp 50 Estradiol Cyp 2;

20 (15) Testosterone Cypionate-Estradiol Cypionate
21 injection; and

22 (16) Testosterone Enanthate-Estradiol Valerate
23 injection.

24 (g) Hallucinogenic substances.

25 (1) Dronabinol (synthetic) in sesame oil and
26 encapsulated in a soft gelatin capsule in a U.S. Food and

1 Drug Administration approved product. Some other names for
2 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
3 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
4 (-)-delta-9-(trans)-tetrahydrocannabinol.

5 (2) (Reserved).

6 (h) The Department may except by rule any compound,
7 mixture, or preparation containing any stimulant or depressant
8 substance listed in subsection (b) from the application of all
9 or any part of this Act if the compound, mixture, or
10 preparation contains one or more active medicinal ingredients
11 not having a stimulant or depressant effect on the central
12 nervous system, and if the admixtures are included therein in
13 combinations, quantity, proportion, or concentration that
14 vitiate the potential for abuse of the substances which have a
15 stimulant or depressant effect on the central nervous system.

16 (Source: P.A. 96-328, eff. 8-11-09; 96-1000, eff. 7-2-10;
17 97-334, eff. 1-1-12.)

18 (720 ILCS 570/401) (from Ch. 56 1/2, par. 1401)

19 Sec. 401. Manufacture or delivery, or possession with
20 intent to manufacture or deliver, a controlled substance, a
21 counterfeit substance, or controlled substance analog. Except
22 as authorized by this Act, it is unlawful for any person
23 knowingly to manufacture or deliver, or possess with intent to
24 manufacture or deliver, a controlled substance other than
25 methamphetamine and other than bath salts as defined in the

1 Bath Salts Prohibition Act sold or offered for sale in a retail
2 mercantile establishment as defined in Section 16-0.1 of the
3 Criminal Code of 2012, a counterfeit substance, or a controlled
4 substance analog. A violation of this Act with respect to each
5 of the controlled substances listed herein constitutes a single
6 and separate violation of this Act. For purposes of this
7 Section, "controlled substance analog" or "analog" means a
8 substance, other than a controlled substance, which is not
9 approved by the United States Food and Drug Administration or,
10 if approved, is not dispensed or possessed in accordance with
11 State or federal law, and that has a chemical structure
12 substantially similar to that of a controlled substance in
13 Schedule I or II, or that was specifically designed to produce
14 an effect substantially similar to that of a controlled
15 substance in Schedule I or II. Examples of chemical classes in
16 which controlled substance analogs are found include, but are
17 not limited to, the following: phenethylamines, N-substituted
18 piperidines, morphinans, ecgonines, quinazolinones,
19 substituted indoles, and arylcycloalkylamines. For purposes of
20 this Act, a controlled substance analog shall be treated in the
21 same manner as the controlled substance to which it is
22 substantially similar.

23 (a) Any person who violates this Section with respect to
24 the following amounts of controlled or counterfeit substances
25 or controlled substance analogs, notwithstanding any of the
26 provisions of subsections (c), (d), (e), (f), (g) or (h) to the

1 contrary, is guilty of a Class X felony and shall be sentenced
2 to a term of imprisonment as provided in this subsection (a)
3 and fined as provided in subsection (b):

4 (1) (A) not less than 6 years and not more than 30
5 years with respect to 15 grams or more but less than
6 100 grams of a substance containing heroin, or an
7 analog thereof;

8 (B) not less than 9 years and not more than 40
9 years with respect to 100 grams or more but less than
10 400 grams of a substance containing heroin, or an
11 analog thereof;

12 (C) not less than 12 years and not more than 50
13 years with respect to 400 grams or more but less than
14 900 grams of a substance containing heroin, or an
15 analog thereof;

16 (D) not less than 15 years and not more than 60
17 years with respect to 900 grams or more of any
18 substance containing heroin, or an analog thereof;

19 (1.5) (A) not less than 6 years and not more than 30
20 years with respect to 15 grams or more but less than
21 100 grams of a substance containing fentanyl, or an
22 analog thereof;

23 (B) not less than 9 years and not more than 40
24 years with respect to 100 grams or more but less than
25 400 grams of a substance containing fentanyl, or an
26 analog thereof;

1 (C) not less than 12 years and not more than 50
2 years with respect to 400 grams or more but less than
3 900 grams of a substance containing fentanyl, or an
4 analog thereof;

5 (D) not less than 15 years and not more than 60
6 years with respect to 900 grams or more of a substance
7 containing fentanyl, or an analog thereof;

8 (2) (A) not less than 6 years and not more than 30
9 years with respect to 15 grams or more but less than
10 100 grams of a substance containing cocaine, or an
11 analog thereof;

12 (B) not less than 9 years and not more than 40
13 years with respect to 100 grams or more but less than
14 400 grams of a substance containing cocaine, or an
15 analog thereof;

16 (C) not less than 12 years and not more than 50
17 years with respect to 400 grams or more but less than
18 900 grams of a substance containing cocaine, or an
19 analog thereof;

20 (D) not less than 15 years and not more than 60
21 years with respect to 900 grams or more of any
22 substance containing cocaine, or an analog thereof;

23 (3) (A) not less than 6 years and not more than 30
24 years with respect to 15 grams or more but less than
25 100 grams of a substance containing morphine, or an
26 analog thereof;

1 (B) not less than 9 years and not more than 40
2 years with respect to 100 grams or more but less than
3 400 grams of a substance containing morphine, or an
4 analog thereof;

5 (C) not less than 12 years and not more than 50
6 years with respect to 400 grams or more but less than
7 900 grams of a substance containing morphine, or an
8 analog thereof;

9 (D) not less than 15 years and not more than 60
10 years with respect to 900 grams or more of a substance
11 containing morphine, or an analog thereof;

12 (4) 200 grams or more of any substance containing
13 peyote, or an analog thereof;

14 (5) 200 grams or more of any substance containing a
15 derivative of barbituric acid or any of the salts of a
16 derivative of barbituric acid, or an analog thereof;

17 (6) 200 grams or more of any substance containing
18 amphetamine or any salt of an optical isomer of
19 amphetamine, or an analog thereof;

20 (6.5) (blank);

21 (6.6) (blank);

22 (7) (A) not less than 6 years and not more than 30
23 years with respect to: (i) 15 grams or more but less
24 than 100 grams of a substance containing lysergic acid
25 diethylamide (LSD), or an analog thereof, or (ii) 15 or
26 more objects or 15 or more segregated parts of an

1 object or objects but less than 200 objects or 200
2 segregated parts of an object or objects containing in
3 them or having upon them any amounts of any substance
4 containing lysergic acid diethylamide (LSD), or an
5 analog thereof;

6 (B) not less than 9 years and not more than 40
7 years with respect to: (i) 100 grams or more but less
8 than 400 grams of a substance containing lysergic acid
9 diethylamide (LSD), or an analog thereof, or (ii) 200
10 or more objects or 200 or more segregated parts of an
11 object or objects but less than 600 objects or less
12 than 600 segregated parts of an object or objects
13 containing in them or having upon them any amount of
14 any substance containing lysergic acid diethylamide
15 (LSD), or an analog thereof;

16 (C) not less than 12 years and not more than 50
17 years with respect to: (i) 400 grams or more but less
18 than 900 grams of a substance containing lysergic acid
19 diethylamide (LSD), or an analog thereof, or (ii) 600
20 or more objects or 600 or more segregated parts of an
21 object or objects but less than 1500 objects or 1500
22 segregated parts of an object or objects containing in
23 them or having upon them any amount of any substance
24 containing lysergic acid diethylamide (LSD), or an
25 analog thereof;

26 (D) not less than 15 years and not more than 60

1 years with respect to: (i) 900 grams or more of any
2 substance containing lysergic acid diethylamide (LSD),
3 or an analog thereof, or (ii) 1500 or more objects or
4 1500 or more segregated parts of an object or objects
5 containing in them or having upon them any amount of a
6 substance containing lysergic acid diethylamide (LSD),
7 or an analog thereof;

8 (7.5) (A) not less than 6 years and not more than 30
9 years with respect to: (i) 15 grams or more but less
10 than 100 grams of a substance listed in paragraph (1),
11 (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
12 (21), (25), or (26) of subsection (d) of Section 204,
13 or an analog or derivative thereof, or (ii) 15 or more
14 pills, tablets, caplets, capsules, or objects but less
15 than 200 pills, tablets, caplets, capsules, or objects
16 containing in them or having upon them any amounts of
17 any substance listed in paragraph (1), (2), (2.1),
18 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
19 (26) of subsection (d) of Section 204, or an analog or
20 derivative thereof;

21 (B) not less than 9 years and not more than 40
22 years with respect to: (i) 100 grams or more but less
23 than 400 grams of a substance listed in paragraph (1),
24 (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
25 (21), (25), or (26) of subsection (d) of Section 204,
26 or an analog or derivative thereof, or (ii) 200 or more

1 pills, tablets, caplets, capsules, or objects but less
2 than 600 pills, tablets, caplets, capsules, or objects
3 containing in them or having upon them any amount of
4 any substance listed in paragraph (1), (2), (2.1),
5 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
6 (26) of subsection (d) of Section 204, or an analog or
7 derivative thereof;

8 (C) not less than 12 years and not more than 50
9 years with respect to: (i) 400 grams or more but less
10 than 900 grams of a substance listed in paragraph (1),
11 (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
12 (21), (25), or (26) of subsection (d) of Section 204,
13 or an analog or derivative thereof, or (ii) 600 or more
14 pills, tablets, caplets, capsules, or objects but less
15 than 1,500 pills, tablets, caplets, capsules, or
16 objects containing in them or having upon them any
17 amount of any substance listed in paragraph (1), (2),
18 (2.1), (2.2), (3), (14.1), (19), (20), (20.1), (21),
19 (25), or (26) of subsection (d) of Section 204, or an
20 analog or derivative thereof;

21 (D) not less than 15 years and not more than 60
22 years with respect to: (i) 900 grams or more of any
23 substance listed in paragraph (1), (2), (2.1), (2.2),
24 (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
25 subsection (d) of Section 204, or an analog or
26 derivative thereof, or (ii) 1,500 or more pills,

1 tablets, caplets, capsules, or objects containing in
2 them or having upon them any amount of a substance
3 listed in paragraph (1), (2), (2.1), (2.2), (3),
4 (14.1), (19), (20), (20.1), (21), (25), or (26) of
5 subsection (d) of Section 204, or an analog or
6 derivative thereof;

7 (8) 30 grams or more of any substance containing
8 pentazocine or any of the salts, isomers and salts of
9 isomers of pentazocine, or an analog thereof;

10 (9) 30 grams or more of any substance containing
11 methaqualone or any of the salts, isomers and salts of
12 isomers of methaqualone, or an analog thereof;

13 (10) 30 grams or more of any substance containing
14 phencyclidine or any of the salts, isomers and salts of
15 isomers of phencyclidine (PCP), or an analog thereof;

16 (10.5) 30 grams or more of any substance containing
17 ketamine or any of the salts, isomers and salts of isomers
18 of ketamine, or an analog thereof;

19 (10.6) 100 grams or more of any substance containing
20 hydrocodone, or any of the salts, isomers and salts of
21 isomers of hydrocodone, or an analog thereof;

22 (10.7) (blank); ~~100 grams or more of any substance~~
23 ~~containing dihydrocodeinone, or any of the salts, isomers~~
24 ~~and salts of isomers of dihydrocodeinone, or an analog~~
25 ~~thereof;~~

26 (10.8) 100 grams or more of any substance containing

1 dihydrocodeine, or any of the salts, isomers and salts of
2 isomers of dihydrocodeine, or an analog thereof;

3 (10.9) 100 grams or more of any substance containing
4 oxycodone, or any of the salts, isomers and salts of
5 isomers of oxycodone, or an analog thereof;

6 (11) 200 grams or more of any substance containing any
7 other controlled substance classified in Schedules I or II,
8 or an analog thereof, which is not otherwise included in
9 this subsection.

10 (b) Any person sentenced with respect to violations of
11 paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
12 involving 100 grams or more of the controlled substance named
13 therein, may in addition to the penalties provided therein, be
14 fined an amount not more than \$500,000 or the full street value
15 of the controlled or counterfeit substance or controlled
16 substance analog, whichever is greater. The term "street value"
17 shall have the meaning ascribed in Section 110-5 of the Code of
18 Criminal Procedure of 1963. Any person sentenced with respect
19 to any other provision of subsection (a), may in addition to
20 the penalties provided therein, be fined an amount not to
21 exceed \$500,000.

22 (b-1) Excluding violations of this Act when the controlled
23 substance is fentanyl, any person sentenced to a term of
24 imprisonment with respect to violations of Section 401, 401.1,
25 405, 405.1, 405.2, or 407, when the substance containing the
26 controlled substance contains any amount of fentanyl, 3 years

1 shall be added to the term of imprisonment imposed by the
2 court, and the maximum sentence for the offense shall be
3 increased by 3 years.

4 (c) Any person who violates this Section with regard to the
5 following amounts of controlled or counterfeit substances or
6 controlled substance analogs, notwithstanding any of the
7 provisions of subsections (a), (b), (d), (e), (f), (g) or (h)
8 to the contrary, is guilty of a Class 1 felony. The fine for
9 violation of this subsection (c) shall not be more than
10 \$250,000:

11 (1) 1 gram or more but less than 15 grams of any
12 substance containing heroin, or an analog thereof;

13 (1.5) 1 gram or more but less than 15 grams of any
14 substance containing fentanyl, or an analog thereof;

15 (2) 1 gram or more but less than 15 grams of any
16 substance containing cocaine, or an analog thereof;

17 (3) 10 grams or more but less than 15 grams of any
18 substance containing morphine, or an analog thereof;

19 (4) 50 grams or more but less than 200 grams of any
20 substance containing peyote, or an analog thereof;

21 (5) 50 grams or more but less than 200 grams of any
22 substance containing a derivative of barbituric acid or any
23 of the salts of a derivative of barbituric acid, or an
24 analog thereof;

25 (6) 50 grams or more but less than 200 grams of any
26 substance containing amphetamine or any salt of an optical

1 isomer of amphetamine, or an analog thereof;

2 (6.5) (blank);

3 (7) (i) 5 grams or more but less than 15 grams of any
4 substance containing lysergic acid diethylamide (LSD), or
5 an analog thereof, or (ii) more than 10 objects or more
6 than 10 segregated parts of an object or objects but less
7 than 15 objects or less than 15 segregated parts of an
8 object containing in them or having upon them any amount of
9 any substance containing lysergic acid diethylamide (LSD),
10 or an analog thereof;

11 (7.5) (i) 5 grams or more but less than 15 grams of any
12 substance listed in paragraph (1), (2), (2.1), (2.2), (3),
13 (14.1), (19), (20), (20.1), (21), (25), or (26) of
14 subsection (d) of Section 204, or an analog or derivative
15 thereof, or (ii) more than 10 pills, tablets, caplets,
16 capsules, or objects but less than 15 pills, tablets,
17 caplets, capsules, or objects containing in them or having
18 upon them any amount of any substance listed in paragraph
19 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
20 (21), (25), or (26) of subsection (d) of Section 204, or an
21 analog or derivative thereof;

22 (8) 10 grams or more but less than 30 grams of any
23 substance containing pentazocine or any of the salts,
24 isomers and salts of isomers of pentazocine, or an analog
25 thereof;

26 (9) 10 grams or more but less than 30 grams of any

1 substance containing methaqualone or any of the salts,
2 isomers and salts of isomers of methaqualone, or an analog
3 thereof;

4 (10) 10 grams or more but less than 30 grams of any
5 substance containing phencyclidine or any of the salts,
6 isomers and salts of isomers of phencyclidine (PCP), or an
7 analog thereof;

8 (10.5) 10 grams or more but less than 30 grams of any
9 substance containing ketamine or any of the salts, isomers
10 and salts of isomers of ketamine, or an analog thereof;

11 (10.6) 50 grams or more but less than 100 grams of any
12 substance containing hydrocodone, or any of the salts,
13 isomers and salts of isomers of hydrocodone, or an analog
14 thereof;

15 (10.7) (blank); ~~50 grams or more but less than 100~~
16 ~~grams of any substance containing dihydrocodeinone, or any~~
17 ~~of the salts, isomers and salts of isomers of~~
18 ~~dihydrocodeinone, or an analog thereof;~~

19 (10.8) 50 grams or more but less than 100 grams of any
20 substance containing dihydrocodeine, or any of the salts,
21 isomers and salts of isomers of dihydrocodeine, or an
22 analog thereof;

23 (10.9) 50 grams or more but less than 100 grams of any
24 substance containing oxycodone, or any of the salts,
25 isomers and salts of isomers of oxycodone, or an analog
26 thereof;

1 (11) 50 grams or more but less than 200 grams of any
2 substance containing a substance classified in Schedules I
3 or II, or an analog thereof, which is not otherwise
4 included in this subsection.

5 (c-5) (Blank).

6 (d) Any person who violates this Section with regard to any
7 other amount of a controlled or counterfeit substance
8 containing ~~dihydrocodeinone~~ or dihydrocodeine or classified in
9 Schedules I or II, or an analog thereof, which is (i) a
10 narcotic drug, (ii) lysergic acid diethylamide (LSD) or an
11 analog thereof, (iii) any substance containing amphetamine or
12 fentanyl or any salt or optical isomer of amphetamine or
13 fentanyl, or an analog thereof, or (iv) any substance
14 containing N-Benzylpiperazine (BZP) or any salt or optical
15 isomer of N-Benzylpiperazine (BZP), or an analog thereof, is
16 guilty of a Class 2 felony. The fine for violation of this
17 subsection (d) shall not be more than \$200,000.

18 (d-5) (Blank).

19 (e) Any person who violates this Section with regard to any
20 other amount of a controlled substance other than
21 methamphetamine or counterfeit substance classified in
22 Schedule I or II, or an analog thereof, which substance is not
23 included under subsection (d) of this Section, is guilty of a
24 Class 3 felony. The fine for violation of this subsection (e)
25 shall not be more than \$150,000.

26 (f) Any person who violates this Section with regard to any

1 other amount of a controlled or counterfeit substance
2 classified in Schedule III is guilty of a Class 3 felony. The
3 fine for violation of this subsection (f) shall not be more
4 than \$125,000.

5 (g) Any person who violates this Section with regard to any
6 other amount of a controlled or counterfeit substance
7 classified in Schedule IV is guilty of a Class 3 felony. The
8 fine for violation of this subsection (g) shall not be more
9 than \$100,000.

10 (h) Any person who violates this Section with regard to any
11 other amount of a controlled or counterfeit substance
12 classified in Schedule V is guilty of a Class 3 felony. The
13 fine for violation of this subsection (h) shall not be more
14 than \$75,000.

15 (i) This Section does not apply to the manufacture,
16 possession or distribution of a substance in conformance with
17 the provisions of an approved new drug application or an
18 exemption for investigational use within the meaning of Section
19 505 of the Federal Food, Drug and Cosmetic Act.

20 (j) (Blank).

21 (Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17.)

22 (720 ILCS 570/402) (from Ch. 56 1/2, par. 1402)

23 Sec. 402. Except as otherwise authorized by this Act, it is
24 unlawful for any person knowingly to possess a controlled or
25 counterfeit substance or controlled substance analog. A

1 violation of this Act with respect to each of the controlled
2 substances listed herein constitutes a single and separate
3 violation of this Act. For purposes of this Section,
4 "controlled substance analog" or "analog" means a substance,
5 other than a controlled substance, which is not approved by the
6 United States Food and Drug Administration or, if approved, is
7 not dispensed or possessed in accordance with State or federal
8 law, and that has a chemical structure substantially similar to
9 that of a controlled substance in Schedule I or II, or that was
10 specifically designed to produce an effect substantially
11 similar to that of a controlled substance in Schedule I or II.
12 Examples of chemical classes in which controlled substance
13 analogs are found include, but are not limited to, the
14 following: phenethylamines, N-substituted piperidines,
15 morphinans, ecgonines, quinazolinones, substituted indoles,
16 and arylcycloalkylamines. For purposes of this Act, a
17 controlled substance analog shall be treated in the same manner
18 as the controlled substance to which it is substantially
19 similar.

20 (a) Any person who violates this Section with respect to
21 the following controlled or counterfeit substances and
22 amounts, notwithstanding any of the provisions of subsections
23 (c) and (d) to the contrary, is guilty of a Class 1 felony and
24 shall, if sentenced to a term of imprisonment, be sentenced as
25 provided in this subsection (a) and fined as provided in
26 subsection (b):

1 (1) (A) not less than 4 years and not more than 15
2 years with respect to 15 grams or more but less than
3 100 grams of a substance containing heroin;

4 (B) not less than 6 years and not more than 30
5 years with respect to 100 grams or more but less than
6 400 grams of a substance containing heroin;

7 (C) not less than 8 years and not more than 40
8 years with respect to 400 grams or more but less than
9 900 grams of any substance containing heroin;

10 (D) not less than 10 years and not more than 50
11 years with respect to 900 grams or more of any
12 substance containing heroin;

13 (2) (A) not less than 4 years and not more than 15
14 years with respect to 15 grams or more but less than
15 100 grams of any substance containing cocaine;

16 (B) not less than 6 years and not more than 30
17 years with respect to 100 grams or more but less than
18 400 grams of any substance containing cocaine;

19 (C) not less than 8 years and not more than 40
20 years with respect to 400 grams or more but less than
21 900 grams of any substance containing cocaine;

22 (D) not less than 10 years and not more than 50
23 years with respect to 900 grams or more of any
24 substance containing cocaine;

25 (3) (A) not less than 4 years and not more than 15
26 years with respect to 15 grams or more but less than

1 100 grams of any substance containing morphine;

2 (B) not less than 6 years and not more than 30
3 years with respect to 100 grams or more but less than
4 400 grams of any substance containing morphine;

5 (C) not less than 6 years and not more than 40
6 years with respect to 400 grams or more but less than
7 900 grams of any substance containing morphine;

8 (D) not less than 10 years and not more than 50
9 years with respect to 900 grams or more of any
10 substance containing morphine;

11 (4) 200 grams or more of any substance containing
12 peyote;

13 (5) 200 grams or more of any substance containing a
14 derivative of barbituric acid or any of the salts of a
15 derivative of barbituric acid;

16 (6) 200 grams or more of any substance containing
17 amphetamine or any salt of an optical isomer of
18 amphetamine;

19 (6.5) (blank);

20 (7) (A) not less than 4 years and not more than 15
21 years with respect to: (i) 15 grams or more but less
22 than 100 grams of any substance containing lysergic
23 acid diethylamide (LSD), or an analog thereof, or (ii)
24 15 or more objects or 15 or more segregated parts of an
25 object or objects but less than 200 objects or 200
26 segregated parts of an object or objects containing in

1 them or having upon them any amount of any substance
2 containing lysergic acid diethylamide (LSD), or an
3 analog thereof;

4 (B) not less than 6 years and not more than 30
5 years with respect to: (i) 100 grams or more but less
6 than 400 grams of any substance containing lysergic
7 acid diethylamide (LSD), or an analog thereof, or (ii)
8 200 or more objects or 200 or more segregated parts of
9 an object or objects but less than 600 objects or less
10 than 600 segregated parts of an object or objects
11 containing in them or having upon them any amount of
12 any substance containing lysergic acid diethylamide
13 (LSD), or an analog thereof;

14 (C) not less than 8 years and not more than 40
15 years with respect to: (i) 400 grams or more but less
16 than 900 grams of any substance containing lysergic
17 acid diethylamide (LSD), or an analog thereof, or (ii)
18 600 or more objects or 600 or more segregated parts of
19 an object or objects but less than 1500 objects or 1500
20 segregated parts of an object or objects containing in
21 them or having upon them any amount of any substance
22 containing lysergic acid diethylamide (LSD), or an
23 analog thereof;

24 (D) not less than 10 years and not more than 50
25 years with respect to: (i) 900 grams or more of any
26 substance containing lysergic acid diethylamide (LSD),

1 or an analog thereof, or (ii) 1500 or more objects or
2 1500 or more segregated parts of an object or objects
3 containing in them or having upon them any amount of a
4 substance containing lysergic acid diethylamide (LSD),
5 or an analog thereof;

6 (7.5) (A) not less than 4 years and not more than 15
7 years with respect to: (i) 15 grams or more but less
8 than 100 grams of any substance listed in paragraph
9 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
10 (20.1), (21), (25), or (26) of subsection (d) of
11 Section 204, or an analog or derivative thereof, or
12 (ii) 15 or more pills, tablets, caplets, capsules, or
13 objects but less than 200 pills, tablets, caplets,
14 capsules, or objects containing in them or having upon
15 them any amount of any substance listed in paragraph
16 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
17 (20.1), (21), (25), or (26) of subsection (d) of
18 Section 204, or an analog or derivative thereof;

19 (B) not less than 6 years and not more than 30
20 years with respect to: (i) 100 grams or more but less
21 than 400 grams of any substance listed in paragraph
22 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
23 (20.1), (21), (25), or (26) of subsection (d) of
24 Section 204, or an analog or derivative thereof, or
25 (ii) 200 or more pills, tablets, caplets, capsules, or
26 objects but less than 600 pills, tablets, caplets,

1 capsules, or objects containing in them or having upon
2 them any amount of any substance listed in paragraph
3 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
4 (20.1), (21), (25), or (26) of subsection (d) of
5 Section 204, or an analog or derivative thereof;

6 (C) not less than 8 years and not more than 40
7 years with respect to: (i) 400 grams or more but less
8 than 900 grams of any substance listed in paragraph
9 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
10 (20.1), (21), (25), or (26) of subsection (d) of
11 Section 204, or an analog or derivative thereof, or
12 (ii) 600 or more pills, tablets, caplets, capsules, or
13 objects but less than 1,500 pills, tablets, caplets,
14 capsules, or objects containing in them or having upon
15 them any amount of any substance listed in paragraph
16 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
17 (20.1), (21), (25), or (26) of subsection (d) of
18 Section 204, or an analog or derivative thereof;

19 (D) not less than 10 years and not more than 50
20 years with respect to: (i) 900 grams or more of any
21 substance listed in paragraph (1), (2), (2.1), (2.2),
22 (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
23 subsection (d) of Section 204, or an analog or
24 derivative thereof, or (ii) 1,500 or more pills,
25 tablets, caplets, capsules, or objects containing in
26 them or having upon them any amount of a substance

1 listed in paragraph (1), (2), (2.1), (2.2), (3),
2 (14.1), (19), (20), (20.1), (21), (25), or (26) of
3 subsection (d) of Section 204, or an analog or
4 derivative thereof;

5 (8) 30 grams or more of any substance containing
6 pentazocine or any of the salts, isomers and salts of
7 isomers of pentazocine, or an analog thereof;

8 (9) 30 grams or more of any substance containing
9 methaqualone or any of the salts, isomers and salts of
10 isomers of methaqualone;

11 (10) 30 grams or more of any substance containing
12 phencyclidine or any of the salts, isomers and salts of
13 isomers of phencyclidine (PCP);

14 (10.5) 30 grams or more of any substance containing
15 ketamine or any of the salts, isomers and salts of isomers
16 of ketamine;

17 (11) 200 grams or more of any substance containing any
18 substance classified as a narcotic drug in Schedules I or
19 II, or an analog thereof, which is not otherwise included
20 in this subsection.

21 (b) Any person sentenced with respect to violations of
22 paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
23 involving 100 grams or more of the controlled substance named
24 therein, may in addition to the penalties provided therein, be
25 fined an amount not to exceed \$200,000 or the full street value
26 of the controlled or counterfeit substances, whichever is

1 greater. The term "street value" shall have the meaning
2 ascribed in Section 110-5 of the Code of Criminal Procedure of
3 1963. Any person sentenced with respect to any other provision
4 of subsection (a), may in addition to the penalties provided
5 therein, be fined an amount not to exceed \$200,000.

6 (c) Any person who violates this Section with regard to an
7 amount of a controlled substance other than methamphetamine or
8 counterfeit substance not set forth in subsection (a) or (d) is
9 guilty of a Class 4 felony. The fine for a violation punishable
10 under this subsection (c) shall not be more than \$25,000.

11 (d) Any person who violates this Section with regard to any
12 amount of anabolic steroid is guilty of a Class C misdemeanor
13 for the first offense and a Class B misdemeanor for a
14 subsequent offense committed within 2 years of a prior
15 conviction.

16 (Source: P.A. 99-371, eff. 1-1-16.)".